Director, Value, Evidence & Outcomes Liaison – Northeast & East

Who We Are

Arcellx is a public, clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. We believe that cell therapies are one of the forward pillars of medicine and our mission is to destroy cancer and advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Our team members are made up of talented innovators and dreamers working from our offices in Rockville, Maryland, and Redwood City, California.

At Arcellx, we hire exceptional people and create a fun, diverse, supportive, and informal environment that allows everyone to do their best work.

Living our core values is essential to maintaining a work environment that is high‑performing, inclusive, and collaborative. We look for candidates who demonstrate strong values alignment and bring different backgrounds, viewpoints, and abilities to the team.

• Start with authenticity:
  We foster an inclusive environment where each person can bring their authentic self to work.
• Think ‘we’ before ‘me’:
  We prioritize collective success, collaborating and supporting one another to achieve our shared goals.
• Embrace the challenge:
  We deliver exceptional results by working with shared determination and a commitment to doing what’s right.

The demand for high-quality health economic and outcomes research (HEOR) and real‑world evidence (RWE) to support drug development and access decisions continues to grow. As part of the Value & Access organization, the VEO Liaison serves as the interface between Arcellx and population‑based decision makers (PHDMs), including payers, pathway organizations, health systems, research institutions, and policy makers. Your work in this role will accelerate patient access and transform healthcare delivery through impactful science, supporting the launch of anitocabtagene autoleucel (anito‑cel), our lead CAR T‑cell therapy for relapsed refractory multiple myeloma.

The VEOL role is dynamic given the complex and ever‑changing US healthcare system, continuous innovation in the medical and pharmaceutical industry, and advances in health information technology and real‑world data. Primary responsibilities include customer engagement and evidentiary support while also enabling collaborations that improve patient outcomes, accelerate equitable patient access, and transform healthcare delivery. This entails serving as Arcellx’s point of contact for PHDMs.

Key activities in this role include the following:

• Deliver and utilize clinical, value, and outcomes evidence including observational research, comparative effectiveness, and economic data to address customer needs.
• Synthesize, communicate, and translate complex information packages and/or data into transparent, relevant, objective and actionable insights for value‑based decision makers.
• Collaborate with PHDMs within an assigned geographic “healthcare ecosystem” to understand and address their information needs.
• Develop and execute the RWE/HEOR strategy collaborating with internal and field‑based medical and commercial partners to deliver outstanding customer experiences.
• Share expertise with customers as their trusted resource on topics related to disease state, Arcellx and competitor products, health outcomes research, quality measures, healthcare policy, technology assessment, economic dynamics, and real‑world evidence.
• Establish valued relationships with PHDMs within assigned accounts at the hospital and payer level.
• Build and maintain understanding of access landscape, including P&T formulary inclusion, pathway development, payer medical policy coverage, and emerging competitive trends.
• Collaborate with relevant internal stakeholders to incorporate access insights into account planning.

• Apply knowledge of clinical, analytic, environmental, and account‑level considerations to facilitate mutually beneficial research collaborations.
• Frequently share customer insights, evidence gaps, environmental trends, and…